{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+A&page=65",
    "query": {
      "intervention": "High Dose Drug A",
      "page": 65
    },
    "page_size": 10
  },
  "pagination": {
    "page": 65,
    "page_size": 10,
    "total_count": 1667,
    "total_pages": 167,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+A&page=66&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+A&page=64&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T05:29:18.749Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07438860",
      "title": "Fluorescence-Guided Imaging of Brain Tumors: A Safety Study Using SBK2-ICG",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Brain Tumors",
        "Glioma"
      ],
      "interventions": [
        {
          "name": "SBK2-ICG",
          "type": "DRUG"
        },
        {
          "name": "Craniotomy (Standard of Care)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Tiffany Hodges",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2026-11-02",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-19T05:29:18.749Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio • Dayton, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Dayton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07438860"
    },
    {
      "nct_id": "NCT00079482",
      "title": "Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "CEP-701",
          "type": "DRUG"
        },
        {
          "name": "high-dose cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cephalon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 224,
      "start_date": "2003-10",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2016-07-21",
      "last_synced_at": "2026-11-19T05:29:18.749Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00079482"
    },
    {
      "nct_id": "NCT02584140",
      "title": "Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "Text Messaging",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Adherence Counseling",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Daily Oral PrEP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 136,
      "start_date": "2016-05",
      "completion_date": "2019-06-14",
      "has_results": true,
      "last_update_posted_date": "2021-07-08",
      "last_synced_at": "2026-11-19T05:29:18.749Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • San Diego, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02584140"
    },
    {
      "nct_id": "NCT04779307",
      "title": "A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "Vedolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 121,
      "start_date": "2021-10-19",
      "completion_date": "2025-07-01",
      "has_results": true,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-11-19T05:29:18.749Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • San Diego, California • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04779307"
    },
    {
      "nct_id": "NCT05585307",
      "title": "Study of Novel Antiretrovirals in Participants With HIV-1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "Bavtavirine",
          "type": "DRUG"
        },
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (Substudy 01)",
          "type": "DRUG"
        },
        {
          "name": "GS-1720",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (Substudy 02)",
          "type": "DRUG"
        },
        {
          "name": "GS-6212",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (Substudy 03)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 49,
      "start_date": "2022-10-26",
      "completion_date": "2024-03-18",
      "has_results": true,
      "last_update_posted_date": "2025-05-08",
      "last_synced_at": "2026-11-19T05:29:18.749Z",
      "location_count": 38,
      "location_summary": "Long Beach, California • Los Angeles, California • San Francisco, California + 14 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05585307"
    },
    {
      "nct_id": "NCT07310563",
      "title": "A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Overweight",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "AMG 133",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 59,
      "start_date": "2024-12-10",
      "completion_date": "2025-05-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-19T05:29:18.749Z",
      "location_count": 1,
      "location_summary": "Los Alamitos, California",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07310563"
    },
    {
      "nct_id": "NCT03788434",
      "title": "Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clostridium Difficile Infection Recurrence",
        "Clostridium Difficile Infection",
        "Clostridium Difficile",
        "Clostridioides Difficile Infection Recurrence",
        "Clostridioides Difficile Infection",
        "Clostridioides Difficile",
        "CDI"
      ],
      "interventions": [
        {
          "name": "VE303",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vedanta Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2019-02-08",
      "completion_date": "2021-09-15",
      "has_results": true,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-11-19T05:29:18.749Z",
      "location_count": 29,
      "location_summary": "Phoenix, Arizona • Jonesboro, Arkansas • Canoga Park, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03788434"
    },
    {
      "nct_id": "NCT02706834",
      "title": "Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dose Finding Study"
      ],
      "interventions": [
        {
          "name": "TAK-828",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2016-03-01",
      "completion_date": "2016-06-17",
      "has_results": true,
      "last_update_posted_date": "2018-10-19",
      "last_synced_at": "2026-11-19T05:29:18.749Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Austin, Texas",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02706834"
    },
    {
      "nct_id": "NCT04990739",
      "title": "Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "MTB-9655",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MetaboMed Inc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-06-30",
      "completion_date": "2024-01-31",
      "has_results": false,
      "last_update_posted_date": "2021-12-17",
      "last_synced_at": "2026-11-19T05:29:18.749Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04990739"
    },
    {
      "nct_id": "NCT01587027",
      "title": "Safety Evaluation of Aminophylline and Methazolamide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mountain Sickness"
      ],
      "interventions": [
        {
          "name": "Aminophylline",
          "type": "DRUG"
        },
        {
          "name": "Methazolamide",
          "type": "DRUG"
        },
        {
          "name": "Aminophylline and Methazolamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Poudre Valley Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 16,
      "start_date": "2011-12",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2017-02-10",
      "last_synced_at": "2026-11-19T05:29:18.749Z",
      "location_count": 1,
      "location_summary": "Loveland, Colorado",
      "locations": [
        {
          "city": "Loveland",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01587027"
    }
  ]
}